MétaCan
Menu
Back to cohort
Record W4413788706 · doi:10.1159/000547359

Polypill and Riskometer to Prevent Stroke and Cognitive Impairment in Primary Health Care (PROMOTE) Randomized Clinical Trial: Rationale and Design

2025· article· en· W4413788706 on OpenAlexaff
Sheila Cristina Ouriques Martins, Michael Brainin, Craig S. Anderson, Philip M. Bath, Graeme J. Hankey, Renato D. Lópes, Otávio Berwanger, Luciano A. Sposato, Thaís Secchi, Brunna Jaeger Teló, Franciele Pereira dos Santos, Jaqueline Radin, Juliana Ellwanger, Danielle A. Pereira, Francine W. Quadros, Liliane Silva, Marcelo Gonçalves, Gabriel Paulo Mantovani, Manoela Ceretta, João Eduardo Bastianello, Arthur Pille, Guilherme Pamplona Bueno de Andrade, Octávio Marques Pontes‐Neto, Gisele Sampaio Silva, Luiz Antônio Nasi, Aline Rigon Zimmer, Diogo O. Souza, Eduardo R. Zimmer, Márcio Rodrigues, Maicon Falavigna, Valery L. Feigin

Bibliographic record

VenueNeuroepidemiology · 2025
Typearticle
Languageen
FieldMedicine
TopicMedication Adherence and Compliance
Canadian institutionsWestern University
Fundersnot available
KeywordsMedicinePolypillRandomized controlled trialStroke (engine)Primary careCognitive impairmentDementiaCognitionPhysical therapyAlternative medicineClinical trialGerontologyPhysical medicine and rehabilitationFamily medicinePsychiatryDiseaseInternal medicine

Abstract

fetched live from OpenAlex

INTRODUCTION: Stroke and dementia have common modifiable risk factors. Current prevention strategies primarily focus on high-risk populations, leaving a gap in addressing the broader population. We report the protocol for a randomized controlled trial (RCT) that aims to evaluate the feasibility, tolerability, and effectiveness of a polypill (valsartan 80 mg, amlodipine 5 mg, and rosuvastatin 10 mg), with and without use of the Stroke Riskometer app, on systolic blood pressure (SBP) and other cardiovascular disease (CVD) risk factors at 9 months after randomization in a population of low to borderline CVD risk. METHODS: A prospective, pragmatic, multicentre, factorial, phase III, placebo-controlled, cluster RCT in low to moderate CVD risk (10-year risk <20%) individuals aged 50-75 years with no prior history of hypertension, diabetes mellitus, stroke, or other CVD, with a SBP of 121-139 mm Hg and at least one lifestyle-related CVD risk factor. Primary care units in Porto Alegre, Brazil, were centrally randomized to either use of the Stroke Riskometer app or standard care for lifestyle modification. All eligible individuals underwent a 28-day open run-in phase using the active medication. Participants who tolerated and had high adherence were randomized to either polypill or placebo, using a minimization process according to age, sex, SBP, cholesterol, and education level. The dual primary outcomes were change in SBP and Life's Simple 7 (LS7) score at 9 months post-randomization. A sample of 354 participants was estimated to provide 80% statistical power (two-sided α = 0.05, β = 0.20) for 6 clusters with intra-cluster correlation of 0.01 to detect a clinically significant 2.5-mm Hg (SD ± 8) difference in SBP change and 0.65 points (SD ± 1.61) difference in the LS7 score at 9 months post-randomization between the polypill/Stroke Riskometer group and placebo/usual care group, assuming 10% lost to follow-up. All analyses were conducted according to the intention-to-treat principle. Regression analysis models (ANCOVA) assessed the differences among the four groups concerning changes in SBP, cholesterol levels, cognitive function, and behavioural risk factors over time. CONCLUSION: The findings will provide critical information to allow the development of primary stroke and CVD prevention strategies in low to borderline CVD risk adults.

Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.

How this classification was reachedexpand

Full frame machine prediction

Teacher imitation

Not calibrated prevalence, not ground truth. Human validation pending. The Gemma side is a direct model label for every work in the frame, read from the title-only record. The Codex side is a classifier learned from the 10,348 direct Codex labels and calibrated to design-weighted sample rates; fields without enough sample support carry no Codex call. Candidate is the union of the two sides; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels.

metaresearch head score (Codex)0.022
metaresearch head score (Gemma)0.021
Version: metacan-v3-hybrid-931329e0061cValidation status: machine_predicted_unvalidated
Candidate categoriesnone
Consensus categoriesnone
DomainCandidate signal: none · Consensus signal: none
Study designCandidate signal: Randomized trial · Consensus signal: Randomized trial
GenreCandidate signal: Methods · Consensus signal: none
Teacher disagreement score0.022
Threshold uncertainty score0.117

Distilled classifier scores by category (both heads)

CategoryCodexGemma
Metaresearch0.0220.021
Meta-epidemiology (narrow)0.0040.002
Meta-epidemiology (broad)0.0060.004
Bibliometrics0.0010.002
Science and technology studies0.0010.003
Scholarly communication0.0030.002
Open science0.0020.001
Research integrity0.0050.003
Insufficient payload (model declined to judge)0.0160.003

Machine scores (provisional)

The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.

Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.

Opus teacher head0.087
GPT teacher head0.425
Teacher spread0.338 · how far apart the two teachers sit on this one work
Validation statusscore_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from it

Classification

machine, unvalidated

Machine predicted; a candidate call from one source (direct Gemma or distilled Codex), not a consensus.

The models applied no category: nothing in the taxonomy fit this work.
Study designRandomized trial
Domainnot available
GenreMethods

How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".

Quick stats

Citations2
Published2025
Admission routes1
Has abstractyes

Explore more

Same venueNeuroepidemiologySame topicMedication Adherence and ComplianceFrench-language works237,207